Witty On Pricing: Oncology 'No Safe Haven'
This article was originally published in Scrip
Executive Summary
"It's time for industry and payers to start thinking about different pricing models, and it's going to require some transparency about what everything costs," said Sir Andrew Witty, speaking to Scrip on 18 April. "Lots of people will say pricing is not an issue in oncology. It's going to be an issue – it's inevitable."
You may also be interested in...
"Crazy" European Orphan Drug Pricing System Has To End
Eurordis head Yann Le Cam outlines his vision for the future of orphan drug pricing in Europe.
Orphan Drug Pricing: More Dialogue And Collaboration Needed, Says EURORDIS
Pharmaceutical companies, payers and other stakeholders need to work more collaboratively if the problems surrounding the pricing and reimbursement of orphan medicines are to be tackled successfully in Europe, says the rare disease organization EURORDIS.
What’s On CEO Andrew Witty’s To-Do List Before Exiting GSK
The company showed signs of stabilization in the first quarter, as Witty insisted his diversified strategy is beginning to pay off. But a new CEO will have to contend with the potential entry of Advair generics.